NBIX241220P85000
- 0.83
- 0.000.00%
Neurocrine Biosciences Newsroom
Neurocrine (NBIX) Receives a Hold From RBC Capital
Stifel Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $166
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $160
Oppenheimer Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $192
Jefferies Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $158
Neurocrine (NBIX) Gets a Buy From Oppenheimer
Neurocrine Biosciences Analyst Ratings
Needham Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating
Evercore Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $175
Neurocrine (NBIX) Gets a Buy From J.P. Morgan
Needham Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating
Neurocrine Biosciences: Balancing Strategic Priorities With Regulatory Challenges – Analyst Maintains Hold Rating
CCORF Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $167
Stifel Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $166
H.C. Wainwright Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $190
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $160 to $192
Neurocrine Price Target Maintained With a $190.00/Share by HC Wainwright & Co.
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $136 to $192
Neurocrine Biosciences Analyst Ratings